Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy.

Gesenberg C, Mathias NR, Xu Y, Crison J, Savant I, Saari A, Good DJ, Hemenway JN, Narang AS, Schartman RR, Zheng N, Buzescu A, Patel J.

Pharm Res. 2019 Oct 21;36(12):164. doi: 10.1007/s11095-019-2698-0.

PMID:
31637544
2.

Meta-analysis of goal-directed fluid therapy using transoesophageal Doppler monitoring in patients undergoing elective colorectal surgery.

Rollins KE, Mathias NC, Lobo DN.

BJS Open. 2019 Jul 4;3(5):606-616. doi: 10.1002/bjs5.50188. eCollection 2019 Oct. Review.

3.

In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopharmaceutical development.

Zane P, Gieschen H, Kersten E, Mathias N, Ollier C, Johansson P, Van den Bergh A, Van Hemelryck S, Reichel A, Rotgeri A, Schäfer K, Müllertz A, Langguth P.

Eur J Pharm Biopharm. 2019 Sep;142:222-231. doi: 10.1016/j.ejpb.2019.06.010. Epub 2019 Jun 21.

PMID:
31233862
4.

Benefits of a contralateral routing of signal device for unilateral Naída CI cochlear implant recipients.

Mosnier I, Lahlou G, Flament J, Mathias N, Ferrary E, Sterkers O, Bernardeschi D, Nguyen Y.

Eur Arch Otorhinolaryngol. 2019 Aug;276(8):2205-2213. doi: 10.1007/s00405-019-05467-9. Epub 2019 May 17.

PMID:
31102018
5.

Bioavailability of protein therapeutics in rats following inhalation exposure: Relevance to occupational exposure limit calculations.

Gould JC, Carvajal I, Davidson T, Graham J, Hillegass J, Julien S, Kozhich A, Wang B, Wei H, Yamniuk AP, Mathias N, Haggerty HG, Graziano M.

Regul Toxicol Pharmacol. 2018 Dec;100:35-44. doi: 10.1016/j.yrtph.2018.10.003. Epub 2018 Oct 3.

PMID:
30291877
6.

Retraction Notice to: Destabilization of Binding to Cofactors and SCFMet30 Is the Rate-Limiting Regulatory Step in Degradation of Polyubiquitinated Met4.

Chandrasekaran S, Deffenbaugh AE, Ford DA, Bailly E, Mathias N, Skowyra D.

Mol Cell. 2018 Apr 19;70(2):381. doi: 10.1016/j.molcel.2018.03.002. No abstract available.

7.

A Rare Finding of Falciform Ligament Thrombosis as a Sequel of Acute Pancreatitis.

Lim HQC, Lee XWJ, Mathias N.

Case Rep Radiol. 2017;2017:2879568. doi: 10.1155/2017/2879568. Epub 2017 Dec 18.

8.

Characterization of a Liquid Crystal System for Sustained Release of a Peptide BMS-686117.

Xu Y, Li V, Li J, Pan D, Langenbucher G, Mathias N.

AAPS PharmSciTech. 2018 Jan;19(1):348-357. doi: 10.1208/s12249-017-0835-9. Epub 2017 Jul 24.

PMID:
28741139
9.

Biopharmaceutical Evaluation and CMC Aspects of Oral Modified Release Formulations.

Chang RK, Mathias N, Hussain MA.

AAPS J. 2017 Sep;19(5):1348-1358. doi: 10.1208/s12248-017-0112-6. Epub 2017 Jul 5.

PMID:
28681160
10.

Benefit of the UltraZoom beamforming technology in noise in cochlear implant users.

Mosnier I, Mathias N, Flament J, Amar D, Liagre-Callies A, Borel S, Ambert-Dahan E, Sterkers O, Bernardeschi D.

Eur Arch Otorhinolaryngol. 2017 Sep;274(9):3335-3342. doi: 10.1007/s00405-017-4651-3. Epub 2017 Jun 29.

PMID:
28664331
11.

Multicentre Evaluation of the Naída CI Q70 Sound Processor: Feedback from Cochlear Implant Users and Professionals.

Martin J, Poncet-Wallet C, Illg A, Perrin-Webb S, Henderson L, Noël-Petroff N, Auletta G, Barezzani MG, Houri K, Group IR, Bagus H, Hoppe U, Humphries J, van Treeck W, Briaire JJ, Brendel M, Mathias N.

Audiol Res. 2016 Dec 22;6(2):160. doi: 10.4081/audiores.2016.160. eCollection 2016 Aug 23.

12.

Survey of Cochlear Implant User Satisfaction with the Neptune™ Waterproof Sound Processor.

Briaire JJ; Indian Research Group, Büchner A, Auletta G, Arroyo H, Zoilo C, Mancini P, Buhagiar R, Vaid N, Mathias N.

Audiol Res. 2016 Apr 20;6(1):146. doi: 10.4081/audiores.2016.146. eCollection 2016 Apr 20.

13.

Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.

Good DJ, Hartley R, Mathias N, Crison J, Tirucherai G, Timmins P, Hussain M, Haddadin R, Koo O, Nikfar F, Fung NK.

Mol Pharm. 2015 Dec 7;12(12):4434-44. doi: 10.1021/acs.molpharmaceut.5b00624. Epub 2015 Nov 4.

PMID:
26536519
14.

Food Effect in Humans: Predicting the Risk Through In Vitro Dissolution and In Vivo Pharmacokinetic Models.

Mathias N, Xu Y, Vig B, Kestur U, Saari A, Crison J, Desai D, Vanarase A, Hussain M.

AAPS J. 2015 Jul;17(4):988-98. doi: 10.1208/s12248-015-9759-z. Epub 2015 May 2.

15.

Application of imaging based tools for the characterisation of hollow spray dried amorphous dispersion particles.

Gamble JF, Ferreira AP, Tobyn M, DiMemmo L, Martin K, Mathias N, Schild R, Vig B, Baumann JM, Parks S, Ashton M.

Int J Pharm. 2014 Apr 25;465(1-2):210-7. doi: 10.1016/j.ijpharm.2014.02.002. Epub 2014 Feb 7.

PMID:
24508807
16.

From bench to humans: formulation development of a poorly water soluble drug to mitigate food effect.

Pandey P, Hamey R, Bindra DS, Huang Z, Mathias N, Eley T, Crison J, Yan B, Perrone R, Vemavarapu C.

AAPS PharmSciTech. 2014 Apr;15(2):407-16. doi: 10.1208/s12249-013-0069-4. Epub 2014 Jan 18.

17.

Assessing the risk of pH-dependent absorption for new molecular entities: a novel in vitro dissolution test, physicochemical analysis, and risk assessment strategy.

Mathias NR, Xu Y, Patel D, Grass M, Caldwell B, Jager C, Mullin J, Hansen L, Crison J, Saari A, Gesenberg C, Morrison J, Vig B, Raghavan K.

Mol Pharm. 2013 Nov 4;10(11):4063-73. doi: 10.1021/mp400426f. Epub 2013 Sep 26.

PMID:
24032349
18.

Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.

Chaturvedula PV, Mercer SE, Pin SS, Thalody G, Xu C, Conway CM, Keavy D, Signor L, Cantor GH, Mathias N, Moench P, Denton R, Macci R, Schartman R, Whiterock V, Davis C, Macor JE, Dubowchik GM.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3157-61. doi: 10.1016/j.bmcl.2013.04.012. Epub 2013 Apr 12.

PMID:
23632269
19.

The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.

Han X, Civiello RL, Conway CM, Cook DA, Davis CD, Degnan AP, Jiang XJ, Macci R, Mathias NR, Moench P, Pin SS, Schartman R, Signor LJ, Thalody G, Tora G, Whiterock V, Xu C, Macor JE, Dubowchik GM.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1870-3. doi: 10.1016/j.bmcl.2013.01.011. Epub 2013 Jan 24. Erratum in: Bioorg Med Chem Lett. 2013 Jun 15;23(12):3674.

PMID:
23402880
20.

Pediatric Evaluation of the ClearVoice™ Speech Enhancement Algorithm in Everyday Life.

Noël-Petroff N, Mathias N, Ulmann C, Abbeele TV.

Audiol Res. 2013 Dec 11;3(1):e9. doi: 10.4081/audiores.2013.e9. eCollection 2013 Jan 2.

21.

The use of modeling tools to drive efficient oral product design.

Mathias NR, Crison J.

AAPS J. 2012 Sep;14(3):591-600. doi: 10.1208/s12248-012-9372-3. Epub 2012 May 30. Review.

22.

Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.

Qian F, Wang J, Hartley R, Tao J, Haddadin R, Mathias N, Hussain M.

Pharm Res. 2012 Oct;29(10):2765-76.

PMID:
22315020
23.

Radioprotective effects of Aegle marmelos (L.) Correa (Bael): a concise review.

Baliga MS, Bhat HP, Pereira MM, Mathias N, Venkatesh P.

J Altern Complement Med. 2010 Oct;16(10):1109-16. doi: 10.1089/acm.2009.0604. Epub 2010 Oct 9. Review.

PMID:
20932194
24.

Non-invasive systemic drug delivery: developability considerations for alternate routes of administration.

Mathias NR, Hussain MA.

J Pharm Sci. 2010 Jan;99(1):1-20. doi: 10.1002/jps.21793. Review.

PMID:
19499570
25.

Retrieval of cement embolus from inferior vena cava after percutaneous vertebroplasty.

Athreya S, Mathias N, Rogers P, Edwards R.

Cardiovasc Intervent Radiol. 2009 Jul;32(4):817-9. doi: 10.1007/s00270-009-9550-6. Epub 2009 Mar 31.

PMID:
19333651
26.

Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117.

Qian F, Mathias N, Moench P, Chi C, Desikan S, Hussain M, Smith RL.

Int J Pharm. 2009 Jan 21;366(1-2):218-20. doi: 10.1016/j.ijpharm.2008.10.020. Epub 2008 Nov 5.

PMID:
19027057
27.

Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.

Degnan AP, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Denton R, Han X, Macci R, Mathias NR, Moench P, Pin SS, Ren SX, Schartman R, Signor LJ, Thalody G, Widmann KA, Xu C, Macor JE, Dubowchik GM.

J Med Chem. 2008 Aug 28;51(16):4858-61. doi: 10.1021/jm800546t. Epub 2008 Jul 30.

PMID:
18665579
28.

Re: multi-detector CT: review of its use in acute GI haemorrhage.

Athreya S, Mathias N.

Clin Radiol. 2008 Aug;63(8):956; author reply 956-7. doi: 10.1016/j.crad.2008.01.015. Epub 2008 Jun 27. No abstract available.

PMID:
18625366
29.

Rat nasal lavage biomarkers to assess preclinical irritation potential of nasal drug formulations and excipients.

Mathias NR, Moench P, Heran C, Hussain MA, Smith RL.

J Pharm Sci. 2009 Feb;98(2):495-502. doi: 10.1002/jps.21449.

PMID:
18506818
30.

Interventional radiology: a web review.

Athreya S, Mathias N, Roberston I.

J Vasc Interv Radiol. 2008 May;19(5):779-81. doi: 10.1016/j.jvir.2008.02.005. Epub 2008 Mar 19.

PMID:
18440470
31.

Modulation of tight junctions does not predict oral absorption of hydrophilic compounds: use of Caco-2 and Calu-3 cells.

Kamath AV, Morrison RA, Mathias NR, Dando SA, Marino AM, Chong S.

Arch Pharm Res. 2007 Aug;30(8):1002-7.

PMID:
17879754
32.

Destabilization of binding to cofactors and SCFMet30 is the rate-limiting regulatory step in degradation of polyubiquitinated Met4.

Chandrasekaran S, Deffenbaugh AE, Ford DA, Bailly E, Mathias N, Skowyra D.

Mol Cell. 2006 Dec 8;24(5):689-699. doi: 10.1016/j.molcel.2006.10.028. Retraction in: Mol Cell. 2018 Apr 19;70(2):381.

33.

Carbopol-mediated paracellular transport enhancement in Calu-3 cell layers.

Li L, Mathias NR, Heran CL, Moench P, Wall DA, Smith RL.

J Pharm Sci. 2006 Feb;95(2):326-35.

PMID:
16374869
34.

Nucleoside transport in primary cultured rabbit tracheal epithelial cells.

Mathias NR, Wu SK, Kim KJ, Lee VH.

J Drug Target. 2005 Sep-Nov;13(8-9):509-19.

PMID:
16332576
35.

A rabbit model for sublingual drug delivery: comparison with human pharmacokinetic studies of propranolol, verapamil and captopril.

Dali MM, Moench PA, Mathias NR, Stetsko PI, Heran CL, Smith RL.

J Pharm Sci. 2006 Jan;95(1):37-44.

PMID:
16307454
36.

Functional and pharmacological mechanisms of nucleoside transport across the basolateral membrane of rabbit tracheal epithelial cells.

Wu SK, Mathias NR, Kim KJ, Lee VH.

Life Sci. 2005 Dec 5;78(3):310-20. Epub 2005 Aug 19.

PMID:
16111717
37.

Identification of residues in the WD-40 repeat motif of the F-box protein Met30p required for interaction with its substrate Met4p.

Brunson LE, Dixon C, LeFebvre A, Sun L, Mathias N.

Mol Genet Genomics. 2005 Jun;273(5):361-70. Epub 2005 May 10.

PMID:
15883825
38.

pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model.

Zhou R, Moench P, Heran C, Lu X, Mathias N, Faria TN, Wall DA, Hussain MA, Smith RL, Sun D.

Pharm Res. 2005 Feb;22(2):188-92.

PMID:
15783065
39.

Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast.

Dixon C, Mathias N, Zweig RM, Davis DA, Gross DS.

Genetics. 2005 May;170(1):47-59. Epub 2005 Mar 2.

40.

The amino-terminal portion of the F-box protein Met30p mediates its nuclear import and assimilation into an SCF complex.

Brunson LE, Dixon C, Kozubowski L, Mathias N.

J Biol Chem. 2004 Feb 20;279(8):6674-82. Epub 2003 Dec 5.

41.

The effect of anesthesia on the pharmacokinetics of sublingually administered verapamil in rabbits.

Moench PA, Heran CL, Stetsko PI, Mathias NR, Wall DA, Hussain MA, Smith RL.

J Pharm Sci. 2003 Sep;92(9):1735-8. No abstract available.

PMID:
12949993
42.
43.

Effect of delivery route on pulmonary response to oncostatin M.

Li HL, Mathias N, Timoszyk J, Stouffer B, Wall D.

J Drug Target. 2002 Feb;10(1):55-62.

PMID:
11996087
44.

Small worlds: how and why.

Mathias N, Gopal V.

Phys Rev E Stat Nonlin Soft Matter Phys. 2001 Feb;63(2 Pt 1):021117. Epub 2001 Jan 26.

PMID:
11308478
45.

The abundance of Met30p limits SCF(Met30p) complex activity and is regulated by methionine availability.

Smothers DB, Kozubowski L, Dixon C, Goebl MG, Mathias N.

Mol Cell Biol. 2000 Nov;20(21):7845-52.

46.
47.

Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.

Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW.

Diabetes Care. 1998 Sep;21(9):1455-61.

PMID:
9727891
48.

Modification of yeast Cdc53p by the ubiquitin-related protein rub1p affects function of the SCFCdc4 complex.

Lammer D, Mathias N, Laplaza JM, Jiang W, Liu Y, Callis J, Goebl M, Estelle M.

Genes Dev. 1998 Apr 1;12(7):914-26.

49.
50.

Cdc53p acts in concert with Cdc4p and Cdc34p to control the G1-to-S-phase transition and identifies a conserved family of proteins.

Mathias N, Johnson SL, Winey M, Adams AE, Goetsch L, Pringle JR, Byers B, Goebl MG.

Mol Cell Biol. 1996 Dec;16(12):6634-43.

Supplemental Content

Loading ...
Support Center